Cryoablation of Small Breast Tumors in Early Stage Breast Cancer
This study examines the use of cryoablation as an alternative to surgery in the treatment of early stage invasive breast cancer. The hypothesis is that cryoablation will complete ablation and destroy the tumor in a selected population of women who may otherwise be adequately treated with surgery.
- Age ≥ 50
- Unifocal primary invasive breast carcinoma diagnosed by core needle biopsy
- Maximum tumor size ≤1.5 cm in its greatest diameter
- Ultrasound visible lesion(s)
- Clinically node negative, hormone receptor positive (+). HER2 negative (-), with <25% intraductal component in the aggregate.
- Unilateral or bilateral disease meeting study criteria
- Physical and emotional ability to undergo baseline and follow-up breast MRIs and serial breast cosmesis analysis
- Patient agrees to receive a 5 year minimum course of endocrine therapy following cryoablation for control of systemic disease
- Prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer
- Ductal carcinoma in-situ with microinvasions (T1mic)
- Multifocal or multicentric invasive breast carcinoma
- Prior or planned neoadjuvant systemic therapy for breast cancer
- Tumor with ≥25% IDC components
Locations & Contacts
Name Not Available
Trial Objectives and Outline
PURPOSE: To determine the rate of successful tumor ablation in patients treated with cryoablation and endocrine therapy in a subset of patients with early stage breast cancer. OUTLINE: 1. Core Biopsy (Pre-Registration) 2. Magnetic Resonance Imaging (Pre-Registration) 3. Tumor Cryoablation 4. Core Biopsy (Post-Cryoablation) 5. Magnetic Resonance Imaging (Post-Cryoablation) 6. Postoperative Follow-up 7. Evaluation of outcomes
Trial Phase & Type
No phase specified
Sanarus Technologies, Inc.
Secondary IDs NCI-2017-00241
Clinicaltrials.gov ID NCT01992250